News

Grey matter atrophy — its loss —  follows a sequential pattern that expands to involve more regions of the brain over time in all multiple sclerosis (MS) patients, regardless of their disease type, a new study reports. Atrophy progression is also similar between relapsing-remitting multiple sclerosis (RRMS) and primary-progressive multiple sclerosis (PPMS)…

The National Institute for Health and Care Excellence, known as NICE, has decided against recommending that Ocrevus be part of public-funded treatments for adults with primary progressive multiple sclerosis (PPMS). The National Health Service (NHS) is the subsidized, publicly funded healthcare system for England, with similar structures…

Protecting the public against an outbreak like the swine flu using GlaxoSmithKline‘s vaccine Arepanrix — or a similar vaccine with an AS03 adjuvant delivery system — does not increase a risk of multiple sclerosis (MS), a population study conducted in Canada reports. The study, “Registry Cohort Study to Determine Risk…

Greater exposure to sunlight during the winter months — part of a person’s lifetime exposure to ultraviolet radiation — can help to lower the risk of multiple sclerosis (MS), a large U.S. cohort study suggests. The study, “Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in…

Long-term exposure to three common air pollutants — fine particulate matter, nitrogen dioxide, and ozone — were not found to be “convincingly” linked to incidence of multiple sclerosis (MS) in a large population study conducted in Canada. The study, “Long-term exposure to air pollution and the incidence of multiple sclerosis: A…

Researchers confirmed that Sativex spray is beneficial in alleviating pain in patients with multiple sclerosis (MS), and also improved their pain sensitivity to cold temperatures. The study reporting the findings, “Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX) in Patients with Multiple Sclerosis: A Study with Quantitative…

The Multiple Sclerosis Association of America (MSAA) recently launched a new version of the My MS Manager, a mobile app designed to provide convenient services to the multiple sclerosis (MS) community. The app is powered by @Point of Care and is available as a free download…

Treating mice in a model of multiple sclerosis (MS) with laquinimod before the onset of symptoms eased inflammation so as to help preserve their vision — lessening damage to the optic nerve and retina, a study from Germany reports. The study, “Laquinimod protects the optic nerve and…

A radioactive probe that might enable imaging tools to effectively monitor what a gene therapy is doing in the brain — important in treating diseases like multiple sclerosis with such a therapy — has been developed at Stanford University. The probe is a kind of radiotracer used successfully in this study…

Genentech‘s Ocrevus (ocrelizumab), approved in March 2017, has fueled a sea change in the treatment of multiple sclerosis (MS) patients in the U.S., leading to an increased interest in disease-modifying therapies (DMTs) for progressive forms of MS. Now, other potential treatment choices for progressive MS forms will likely…

A new fluorescent imaging strategy allows researchers to track T-cells and further understand their dynamics in vivo, giving them insight into what happens when these immune cells attack myelin in a mouse model of multiple sclerosis (MS). The new technology was reported in the study, “A timer for…

A first patient has been enrolled in a single-site trial to evaluate the potential of electrical stimulation, called  Electroceutical Therapy, in reducing brain injury, Endonovo Therapeutics, the therapy’s developer, announced. Electroceutical Therapy is a non-invasive and wearable electronic device that uses pulsed electromagnetic fields (PEMF) to stimulate the central nervous system.

Axim Biotech announced that its way of extracting and purifying THC (delta-9-tetrahydrocannabinol) — an active compound in medical cannabis — has been approved to receive a patent. The notice of allowance for patient No. 15/146668 came in letter from the United States Patent and Trademark Office (USPTO), Axim said in…

MyHealthTeams together with Biogen launched a new online tool center, called MS and Cognition Resource Center, to educate multiple sclerosis (MS) patients on brain health, and to help them better understand how MS impacts the brain and how they might manage the cognitive challenges the disease brings.

New retrospective analysis of the Phase 3 CLARITY study (NCT00213135) shows that treatment with Mavenclad (cladribine tablets) improved annualized relapse rate and magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of their age. Moreover, the effectiveness of Mavenclad was comparable to five standard therapies…

Scientists have uncovered the molecular mechanism by which the genetic variant HLA-DRB1*15:01 is the strongest risk factor for multiple sclerosis, new research shows. Analyzing several studies, researchers found that the risk linked…

When a progressively debilitating disease like multiple sclerosis (MS) causes a patient to feel physically “wiped out” after a simple daily activity, such as a shower, it is of utmost importance for these individuals and the people in their support system to understand how they can maintain independence for…

Magnetic resonance imaging (MRI) used to assess inflammation in multiple sclerosis (MS) patients should include scans of the spinal cord and not be restricted to the brain, because brain scans alone risk underestimating disease progression, a study suggests. These results were shared in the presentation, “Measuring disease activity in…

Measuring the response of the pupil to light stimulating the eye is a non-invasive and easy way to assess multiple sclerosis (MS) severity and progression, researchers report. A clinical study found that poor, or dysfunctional, pupil response was associated with longer disease duration and greater disease severity in relapsing-remitting multiple…

Levels of neurofilament light chain are a reliable predictor of disease worsening and progression in relapsing-remitting MS (RRMS) patients, a new study shows. Moreover, treatment with Gilenya (fingolimod), marketed by Novartis, can reduce the levels of NfL for up to 10 years. These findings were shared recently in the presentation “…

New treatment guidelines for multiple sclerosis (MS) patients in Europe were set in place through an initiative undertaken by the European Academy of Neurology (EAN) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Launched in parallel to the 4th Congress of the European Academy…

Analysis of post-mortem brain samples from multiple sclerosis (MS) patients and healthy individuals (without neurologic disease) showed that while signs of Epstein-Barr virus (EBV) infection are present in both groups of brains, EBV-positive immune cells were more prevalent and densely populated in the MS brain. The study reporting those findings,…

Long-term treatment with Ocrevus (ocrelizumab)  — as well as switching from Rebif (interferon beta-1a) to Ocrevus — leads to a significant and sustained reduction in disease activity in relapsing forms of multiple sclerosis (MS). These previously reported findings are further supported by the latest results drawn from pooled data…

A new clinical trial will be the first in the world to recognize the importance of retaining hand function for wheelchair-bound patients with primary progressive MS (PPMS), according to a press release from Queen Mary University of London. The international trial, which will be conducted by a…

The Multiple Sclerosis Association of America (MSAA) announced that it will expand its MRI Access Fund to help meet the growing demand for magnetic resonance imaging (MRI) tests within the multiple sclerosis (MS) community. The fund is designed to help cover the costs of brain and spinal MRI scans…

Treatment with Ocrevus (ocrelizumab) slows disability progression in primary progressive multiple sclerosis (PPMS) in ways that may be of considerable importance to patients — including the possibility of delaying the need for a wheelchair by up to seven years, according to new data from a Phase 3…

Researchers have unveiled a new cell death mechanism called pyroptosis — also known as “fiery death” — as a main factor driving neurodegeneration and loss of myelin in people with multiple sclerosis (MS). An inhibitor of pyroptosis, currently undergoing testing in human clinical trials for epilepsy, decreased central nervous system inflammation…

Young adults at age 20 who are obese and smoke are not only at a higher risk of developing relapsing multiple sclerosis — those who become MS patients after age 20 are also more likely to advance to secondary progressive MS more quickly, researchers in Sweden report. But the link…

Myomo, a wearable medical robotics company, announced that MyoPro — its myoelectric orthosis or powered brace — is now available for use by teenagers with paralyzed or weakened arms due to injuries or neurological disorders such as multiple sclerosis (MS). MyoPro is a lightweight wearable device that helps restore functionality…

Gilenya (fingolimod) and Tecfidera (dimethyl fumarate) are equally effective as first-line treatments in people with relapsing-remitting multiple sclerosis (RRMS), but Gilenya may be of slightly more benefit to those who switch from a previous injectable therapy, according to a real-world study of patients in Italy. The study, “…